Rabies virus

Global Dog Vaccines Market Size/Share Envisaged to Reach USD 2,708.28 Million By 2032, at 5.7% CAGR: Research by Polaris Market Research

Retrieved on: 
Thursday, January 18, 2024
Parvoviridae, Rabies, Health, RNA, Distemper, Rabies virus, Dog, Small RNA, CIRDC, Vaccination, Bacteria, Acquisition, Disease, Virus, Immunity, Vaccine, Bispecific monoclonal antibody, Immune system

The escalating current of pet possession and the growing circumstance of pet humanization are causing the market to grow.

Key Points: 
  • The escalating current of pet possession and the growing circumstance of pet humanization are causing the market to grow.
  • The dog vaccine market segmentation is primarily based on vaccine type, disease type, duration of immunity, route of administration, and region.
  • The dog vaccine market size is expanding as more people acquire dogs, and there is a correlating escalation in demand for precautionary healthcare estimates involving vaccinations.
  • The dog vaccine market trends include the existence of several productive proxies for the CIRDC, encouraging the continual advancement of contemporary vaccines.

Global mRNA Vaccine Market Research Report 2023: On-going Clinical Trials, Drug Pipeline, Mergers & Acquisitions, & Product Launches - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023
Health, Pharmaceutical, Perelman School of Medicine at the University of Pennsylvania, Pharmacology, Infection, ClinicalTrials.gov, Vaccine, SARS-CoV-2, RNA, Antigen, Biotechnology, Mortality, Penn, Mutation, Safety, HIV, Cytokine, University, TSA, Research, Cell, Protein, Arcturus Therapeutics, Application, Death, COVID-19 vaccine, Pfizer, Growth, Genome, Vaccination, Lipid, COVID-19, Risk, Viral, Immunity, TAA, Competition, Messenger, DSM-IV codes, MRNA vaccine, Cancer, Investment, Therapy, Patient, Toxicity, Zika virus, Rabies virus, DNA

Global mRNA vaccine market is poised to grow at an impressive rate to 2028 on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others.

Key Points: 
  • Global mRNA vaccine market is poised to grow at an impressive rate to 2028 on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others.
  • The global mRNA vaccine market experiences growth driven by the increasing occurrence of cancer, genetic anomalies, and viral infections.
  • This has prompted numerous biotechnology and pharmaceutical companies, along with academic and research institutions, to engage in research, development, and clinical trials for various mRNA vaccines.
  • This, in turn, creates promising prospects for the global mRNA vaccine market during the forecast period.

Is it okay to kiss your pet? The risk of animal-borne diseases is small, but real

Retrieved on: 
Monday, September 4, 2023
Salmonellosis, Infection, Human, Food, Rabies virus, Bird, Disease, Toxoplasma gondii, Parasitism, Prevalence, Bartonella henselae, Face, Aerosol, Turtle, Campylobacteriosis, Dog, Toxoplasmosis, MRSA, Biting, Fungus, Hygiene, Cat, Thought, Mycobacterium, Giardiasis, Animal, Soil, Population, Psittacosis, Risk, Water, Pet, Rabies, Bacteria, Genetically modified bacteria, Birth, Death, Scratch, Virus, Meningitis, Pneumonia, Mouth, Saliva, Pet industry, Medical imaging, Vaccine, Trapping, Veterinary medicine, Animal husbandry, Pig, Poultry farming, Toy, Zoonosis

Pet ownership is at an all-time high, with a recent survey finding 69% of Australian households have at least one pet.

Key Points: 
  • Pet ownership is at an all-time high, with a recent survey finding 69% of Australian households have at least one pet.
  • We spend an estimated A$33 billion every year on caring for our fur babies.
  • But some, such as pregnant people and those with weakened immune systems, are at greater risk of getting sick from animals.

What diseases can pets carry?

    • Infectious diseases that move from animals to humans are called zoonotic diseases or zoonoses.
    • Zoonoses can be transmitted directly from pets to humans, such as through contact with saliva, bodily fluids and faeces, or indirectly, such as through contact with contaminated bedding, soil, food or water.
    • Both dogs and cats are also reservoirs for methicillin-resistant bacterium Staphylococcus aureus (MRSA), with close contact with pets identified as an important risk factor for zoonotic transmission.
    • Read more:
      Cats carry diseases that can be deadly to humans, and it's costing Australia $6 billion every year

Birds, turtles and fish can also transmit disease

    • Pet birds can occasionally transmit psittacosis, a bacterial infection which causes pneumonia.
    • Contact with pet turtles has been linked to Salmonella infections in humans, particularly in young children.
    • Even pet fish have been linked to a range of bacterial infections in humans, including vibriosis, mycobacteriosis and salmonellosis.
    • Close contact with animals – and some behaviours in particular – increase the risk of zoonotic transmission.

What should I do if I’m worried about catching a disease from my pet?


    There are a number of good hygiene and pet husbandry practices that can reduce your risk of becoming sick. These include:
    It is especially important for those who are at a higher risk of illness to take precautions to reduce their exposure to zoonotic pathogens. And if you’re thinking about getting a pet, ask your vet which type of animal would best suit your personal circumstances.

    Read more:
    One in three people are infected with _Toxoplasma_ parasite – and the clue could be in our eyes

Companion Animal Diagnostics Market to Reach USD 6.88 Billion, Globally, by 2031 at 8.6% CAGR: Allied Market Research

Retrieved on: 
Wednesday, August 17, 2022
NCBI, Rabies virus, Zoonosis, Industry, Diagnosis, Population, Technology, Growth, Dog, Cat, Incidence, Prevalence, Income, Clinical urine tests, Conditional sentence, Skin, Awareness, Infection, CAGR, Severe acute respiratory syndrome coronavirus 2, Research, COVID-19, Molecular diagnostics, Animal, Health, Adoption, Medical device, Vaccine, Pet, Hematology, Virology, Parasitology, University, Bacteriology

PORTLAND, Ore., Aug. 17, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, 'Companion Animal Diagnostics Market By Technology (Clinical Biochemistry, Immunodiagnostics, Molecular Diagnostics, Hematology, Urinalysis, Others), By Application (Clinical Pathology, Bacteriology, Virology, Parasitology, Other Applications), By Animal Type (Dogs, Cats, Others), By End User (Diagnostic Labs, Veterinary Hospitals and Clinics, Point-Of-Care and In-House Testing, Research Institutes and Universities): Global Opportunity Analysis and Industry Forecast, 2021-2031.' According to the report, the global companion animal diagnostics industry was estimated at $2.99 billion in 2021, and is anticipated to hit $6.88 billion by 2031, registering a CAGR of 8.6% from 2022 to 2031. The report offers an explicit analysis of the changing market trends, top segments, key investment pockets, value chain, competitive scenario, and regional landscape. The market study is exclusively meant to help the readers with a complete valuation of industry analysis and trends.

Key Points: 
  • According to the report, the global companion animal diagnostics industry was estimated at $2.99 billion in 2021, and is anticipated to hit $6.88 billion by 2031, registering a CAGR of 8.6% from 2022 to 2031.
  • This factor had a positive impact on the global companion animal diagnostics market.
  • Based on technology, the clinical biochemistry segment held around one-third of the global companion animal diagnostics market revenue in 2021, and is expected to lead the trail by 2031.
  • By animal type, the dogs segment contributed to nearly half of the global companion animal diagnostics market share in 2021, and is expected to retain its dominance by 2031.

Companion Animal Diagnostics Market to Reach USD 6.88 Billion, Globally, by 2031 at 8.6% CAGR: Allied Market Research

Retrieved on: 
Wednesday, August 17, 2022
NCBI, Rabies virus, Zoonosis, Industry, Diagnosis, Population, Technology, Growth, Dog, Cat, Incidence, Prevalence, Income, Clinical urine tests, Conditional sentence, Skin, Awareness, Infection, CAGR, Severe acute respiratory syndrome coronavirus 2, Research, COVID-19, Molecular diagnostics, Animal, Health, Adoption, Medical device, Vaccine, Pet, Hematology, Virology, Parasitology, University, Bacteriology

PORTLAND, Ore., Aug. 17, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, 'Companion Animal Diagnostics Market By Technology (Clinical Biochemistry, Immunodiagnostics, Molecular Diagnostics, Hematology, Urinalysis, Others), By Application (Clinical Pathology, Bacteriology, Virology, Parasitology, Other Applications), By Animal Type (Dogs, Cats, Others), By End User (Diagnostic Labs, Veterinary Hospitals and Clinics, Point-Of-Care and In-House Testing, Research Institutes and Universities): Global Opportunity Analysis and Industry Forecast, 2021-2031.' According to the report, the global companion animal diagnostics industry was estimated at $2.99 billion in 2021, and is anticipated to hit $6.88 billion by 2031, registering a CAGR of 8.6% from 2022 to 2031. The report offers an explicit analysis of the changing market trends, top segments, key investment pockets, value chain, competitive scenario, and regional landscape. The market study is exclusively meant to help the readers with a complete valuation of industry analysis and trends.

Key Points: 
  • According to the report, the global companion animal diagnostics industry was estimated at $2.99 billion in 2021, and is anticipated to hit $6.88 billion by 2031, registering a CAGR of 8.6% from 2022 to 2031.
  • This factor had a positive impact on the global companion animal diagnostics market.
  • Based on technology, the clinical biochemistry segment held around one-third of the global companion animal diagnostics market revenue in 2021, and is expected to lead the trail by 2031.
  • By animal type, the dogs segment contributed to nearly half of the global companion animal diagnostics market share in 2021, and is expected to retain its dominance by 2031.

Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID

Retrieved on: 
Monday, August 15, 2022
U.S. Securities and Exchange Commission, GLOBE, Brain, Knowledge, RN, Research, Method, Patient, Monocyte, TBIA, Reardon, Ebola, Immune system, Technology, Neuron, Infection, Cell cycle, Lymphocyte, Biotechnology, Neurodegeneration, IRB, Pressure, OTCQB, Vaccine, Amazon, Preprint, RNA transfection, Apoptosis, Rabies virus, PASC, Cancer, Cell, MERS, COVID-19, Hospital, Synthase, Virus, ResearchGate, Vaccination, Solution, Severe acute respiratory syndrome coronavirus 2, PCR, Pardi, FDA, Legislation, Plasma, Zika virus, Company, TMB-2, Alzheimer's disease, Cancer immunotherapy, Pharmaceutical industry, Medical imaging, Pharma, COVID

There is an urgency for alternative solutions to provide protection against Long COVID.

Key Points: 
  • There is an urgency for alternative solutions to provide protection against Long COVID.
  • Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken each day that provides maximum immune support.
  • Preliminary data from an ongoing IRB-waived study of customers who used the products to assist with their COVID and Long COVID were recently announced.
  • Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, Long COVID and, potentially, pediatric COVID-19.

Molecular Targeting Technologies, Inc., Thomas Jefferson University and North China Pharmaceutical Co., Ltd Announced the Chinese Approval for a Rabies Drug

Retrieved on: 
Wednesday, January 26, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Conference, Faculty, Commerce, Rabies, Death, Evans Blue, Science, Industry, WHO, National, TJU, Partnership, Patient, Thomas Jefferson University, Professor, NMPA, Textile, Radiopharmaceutical, Student, Medicine, Research, R, Post-exposure prophylaxis, NCPC, Pharmacy, Rabies virus, Technology, Doctor of Philosophy, Architecture, Chinese, Safety, Health, EB, CEO, Cancer, Vaccine, Pharmaceutical industry, PRC, Engineering

Molecular Targeting Technologies, Inc., (MTTI) announced that the Chinese NMPA has approved a rabies virus neutralizing, fully human antibody, Ormutivimab for post-exposure prophylaxis.

Key Points: 
  • Molecular Targeting Technologies, Inc., (MTTI) announced that the Chinese NMPA has approved a rabies virus neutralizing, fully human antibody, Ormutivimab for post-exposure prophylaxis.
  • Ormutivimab was invented at Thomas Jefferson University and licensed to MTTI which has conducted trials in China in partnership with the North China Pharmaceutical Co., Ltd (NCPC).
  • Rose Ritts, PhD, Executive Vice President and Chief Innovation Officer for Jefferson Health & Thomas Jefferson University notes, Jefferson is excited to see Ormutivimab gain approval.
  • North China Pharmaceutical Group New Drug Research & Development Co., Ltd. (NCPC R&D) is a wholly owned subsidiary of NCPC located in Shijiazhuang, Hebei Province, PRC.

2021 World Rabies Day Initiative for Remote Indigenous Communities in Canada

Retrieved on: 
Tuesday, September 28, 2021
Canadian Food Inspection Agency, Rabies, Red fox, Animal, Human, Rabies virus, Vaccine, Climate change, Solution, Health, Population, Fox, Cree, Public health, CEO, Dog, Access, Love, Risk, COVID-19, Veterinary biologic, World Rabies Day, Safety, Vaccination, GLOBE

GUELPH, Ontario, Sept. 28, 2021 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is pleased to announce the launch of its 2021 World Rabies Day Initiative for Remote Indigenous Communities in Canada.

Key Points: 
  • GUELPH, Ontario, Sept. 28, 2021 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is pleased to announce the launch of its 2021 World Rabies Day Initiative for Remote Indigenous Communities in Canada.
  • Access to rabies vaccinations for dogs is the cornerstone of rabies prevention and control around the world; yet for decades Canadas remote Indigenous communities have faced significant challenges with accessing this basic prevention tool.
  • Access to basic animal health care, including rabies vaccinations, is important to ensuring public health and safety in all communities, but especially in our remote Indigenous communities.
  • On World Rabies Day 2021, CAHI encourages Canadas remote Indigenous communities to learn more about how they can access rabies vaccines for the dogs in their community and to contact us for more information on how we can assist.